Transforming Computational Pharmacy in Drug Discovery and Development: Integrating CADD, Bioinformatics, Artificial Intelligence, and Pharmacometric Modeling
DOI:
https://doi.org/10.59890/mjst.v3i8.313Keywords:
Psychometrics; Psychological Measurement; Validity; Reliability; Item Response Theory; Computerized Adaptive Testing; Process Data; Artificial Intelligence; Algorithmic Fairness; Digital EthicsAbstract
Computational pharmacy has evolved from using molecular modeling and quantitative structure–activity relationship (QSAR) to a multidisciplinary ecosystem that integrates computer-aided drug design (CADD), bioinformatics, artificial intelligence (AI), molecular simulation, as well as pharmacokinetic and systems pharmacology modeling. This article aims to analyze how the convergence of these technologies shapes the workflow of modern drug discovery and development, and to identify opportunities, limitations, and research priorities that determine the translation of computational results into credible pharmaceutical decisions. The writing uses a qualitative literature review with an interpretative synthesis of reputable journal articles mainly published between 2020 and 2026. The review shows that the main value of computational pharmacy doesn't come from a single algorithm, but from the integration of the data–model–experiment cycle: databases and structure predictions expand target space; virtual screening, molecular dynamics, and free-energy calculations prioritize candidates; AI speeds up prediction and generative design; while PBPK and quantitative systems pharmacology bridge molecular findings to predictions of exposure, response, and populations. However, data quality, domain applicability, bias, interpretability, reproducibility, experimental validation, and regulatory acceptance still remain major challenges. The article concludes that the future of computational pharmacy will be shaped by hybrid physics- and data-based models, closed-loop experimentation, validated digital twins, and transparent, auditable model governance
References
Akdel, M. et al. (2022) ‘A structural biology community assessment of AlphaFold2 applications’, Nature Structural & Molecular Biology, 29, pp. 1056–1067. doi: 10.1038/s41594-022-00849-w. Available at: https://doi.org/10.1038/s41594-022-00849-w (Accessed: 14 August 2026).
Atanasov, A.G. et al. (2021) ‘Natural products in drug discovery: advances and opportunities’, Nature Reviews Drug Discovery, 20, pp. 200–216. doi: 10.1038/s41573-020-00114-z. Available at: https://doi.org/10.1038/s41573-020-00114-z (Accessed: 14 August 2026).
Bai, J.P.F. et al. (2021) ‘Quantitative systems pharmacology: landscape analysis of regulatory submissions to the US Food and Drug Administration’, CPT: Pharmacometrics & Systems Pharmacology, 10, pp. 1479–1484. doi: 10.1002/psp4.12709. Available at: https://doi.org/10.1002/psp4.12709 (Accessed: 14 August 2026).
Bai, J.P.F., Earp, J.C., Strauss, D.G. and Zhu, H. (2020) ‘A perspective on quantitative systems pharmacology applications to clinical drug development’, CPT: Pharmacometrics & Systems Pharmacology, 9, pp. 675–677. doi: 10.1002/psp4.12567. Available at: https://doi.org/10.1002/psp4.12567 (Accessed: 14 August 2026).
Barry, E.S., Merkebu, J. and Varpio, L. (2022) ‘State-of-the-art literature review methodology: a six-step approach for knowledge synthesis’, Perspectives on Medical Education, 11, pp. 281–288. doi: 10.1007/s40037-022-00725-9. Available at: https://doi.org/10.1007/s40037-022-00725-9 (Accessed: 14 August 2026).
Bender, A. and Cortés-Ciriano, I. (2021a) ‘Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: ways to make an impact, and why we are not there yet’, Drug Discovery Today, 26(2), pp. 511–524. doi: 10.1016/j.drudis.2020.12.009. Available at: https://doi.org/10.1016/j.drudis.2020.12.009 (Accessed: 14 August 2026).
Bender, A. and Cortés-Ciriano, I. (2021b) ‘Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data’, Drug Discovery Today, 26(4), pp. 1040–1052. doi: 10.1016/j.drudis.2020.11.037. Available at: https://doi.org/10.1016/j.drudis.2020.11.037 (Accessed: 14 August 2026).
Bloomingdale, P. et al. (2021) ‘Quantitative systems pharmacology in neuroscience: novel methodologies and technologies’, CPT: Pharmacometrics & Systems Pharmacology, 10(5), pp. 412–419. doi: 10.1002/psp4.12607. Available at: https://doi.org/10.1002/psp4.12607 (Accessed: 14 August 2026).
Brunt, D., Lakernick, P.M. and Wu, C. (2022) ‘Discovering new potential inhibitors to SARS-CoV-2 RNA dependent RNA polymerase via high throughput virtual screening and molecular dynamics simulations’, Scientific Reports, 12, 19986. doi: 10.1038/s41598-022-24695-4. Available at: https://doi.org/10.1038/s41598-022-24695-4 (Accessed: 14 August 2026).
Burley, S.K. et al. (2021) ‘RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences’, Nucleic Acids Research, 49(D1), pp. D437–D451. doi: 10.1093/nar/gkaa1038. Available at: https://doi.org/10.1093/nar/gkaa1038 (Accessed: 14 August 2026).
Cramer, P. (2021) ‘AlphaFold2 and the future of structural biology’, Nature Structural & Molecular Biology, 28, pp. 704–705. doi: 10.1038/s41594-021-00650-1. Available at: https://doi.org/10.1038/s41594-021-00650-1 (Accessed: 14 August 2026).
Elbadawi, M., Gaisford, S. and Basit, A.W. (2021) ‘Advanced machine-learning techniques in drug discovery’, Drug Discovery Today, 26(3), pp. 769–777. doi: 10.1016/j.drudis.2020.12.003. Available at: https://doi.org/10.1016/j.drudis.2020.12.003 (Accessed: 14 August 2026).
Furlong, D.E. and Lester, J.N. (2023) ‘Toward a practice of qualitative methodological literature reviewing’, Qualitative Inquiry, 29(6), pp. 669–677. doi: 10.1177/10778004221131028. Available at: https://doi.org/10.1177/10778004221131028 (Accessed: 14 August 2026).
Gallo, K. et al. (2021) ‘PROMISCUOUS 2.0: a resource for drug-repositioning’, Nucleic Acids Research, 49(D1), pp. D1373–D1380. doi: 10.1093/nar/gkaa1061. Available at: https://doi.org/10.1093/nar/gkaa1061 (Accessed: 14 August 2026).
Gao, W. and Coley, C.W. (2020) ‘The synthesizability of molecules proposed by generative models’, Journal of Chemical Information and Modeling, 60(12), pp. 5714–5723. doi: 10.1021/acs.jcim.0c00174. Available at: https://doi.org/10.1021/acs.jcim.0c00174 (Accessed: 14 August 2026).
Gircha, A.I. et al. (2023) ‘Hybrid quantum-classical machine learning for generative chemistry and drug design’, Scientific Reports, 13, 8250. doi: 10.1038/s41598-023-32703-4. Available at: https://doi.org/10.1038/s41598-023-32703-4 (Accessed: 14 August 2026).
Gorgulla, C. et al. (2020) ‘An open-source drug discovery platform enables ultra-large virtual screens’, Nature, 580, pp. 663–668. doi: 10.1038/s41586-020-2117-z. Available at: https://doi.org/10.1038/s41586-020-2117-z (Accessed: 14 August 2026).
Grebner, C., Matter, H., Plowright, A.T. and Hessler, G. (2020) ‘Automated de novo design in medicinal chemistry: which types of chemistry does a generative neural network learn?’, Journal of Medicinal Chemistry, 63(16), pp. 8809–8823. doi: 10.1021/acs.jmedchem.9b02044. Available at: https://doi.org/10.1021/acs.jmedchem.9b02044 (Accessed: 14 August 2026).
Grzegorzewski, J. et al. (2021) ‘PK-DB: pharmacokinetics database for individualized and stratified computational modeling’, Nucleic Acids Research, 49(D1), pp. D1358–D1364. doi: 10.1093/nar/gkaa990. Available at: https://doi.org/10.1093/nar/gkaa990 (Accessed: 14 August 2026).
Hekkelman, M.L., de Vries, I., Joosten, R.P. and Perrakis, A. (2023) ‘AlphaFill: enriching AlphaFold models with ligands and cofactors’, Nature Methods, 20, pp. 205–213. doi: 10.1038/s41592-022-01685-y. Available at: https://doi.org/10.1038/s41592-022-01685-y (Accessed: 14 August 2026).
Hermann, J. et al. (2023) ‘Ab initio quantum chemistry with neural-network wavefunctions’, Nature Reviews Chemistry, 7, pp. 692–709. doi: 10.1038/s41570-023-00516-8. Available at: https://doi.org/10.1038/s41570-023-00516-8 (Accessed: 14 August 2026).
Jamei, M. (2020) ‘Where do PBPK models stand in pharmacometrics and systems pharmacology?’, CPT: Pharmacometrics & Systems Pharmacology, 9(2), pp. 75–76. doi: 10.1002/psp4.12493. Available at: https://doi.org/10.1002/psp4.12493 (Accessed: 14 August 2026).
Jiménez-Luna, J., Grisoni, F. and Schneider, G. (2020) ‘Drug discovery with explainable artificial intelligence’, Nature Machine Intelligence, 2, pp. 573–584. doi: 10.1038/s42256-020-00236-4. Available at: https://doi.org/10.1038/s42256-020-00236-4 (Accessed: 14 August 2026).
Jumper, J. et al. (2021) ‘Highly accurate protein structure prediction with AlphaFold’, Nature, 596, pp. 583–589. doi: 10.1038/s41586-021-03819-2. Available at: https://doi.org/10.1038/s41586-021-03819-2 (Accessed: 14 August 2026).
Kim, S. et al. (2021) ‘PubChem in 2021: new data content and improved web interfaces’, Nucleic Acids Research, 49(D1), pp. D1388–D1395. doi: 10.1093/nar/gkaa971. Available at: https://doi.org/10.1093/nar/gkaa971 (Accessed: 14 August 2026).
King, E., Aitchison, E., Li, H. and Luo, R. (2021) ‘Recent developments in free energy calculations for drug discovery’, Frontiers in Molecular Biosciences, 8, 712085. doi: 10.3389/fmolb.2021.712085. Available at: https://doi.org/10.3389/fmolb.2021.712085 (Accessed: 14 August 2026).
Lee, S. et al. (2023) ‘Evaluating the evidence for exponential quantum advantage in ground-state quantum chemistry’, Nature Communications, 14, 1952. doi: 10.1038/s41467-023-37587-6. Available at: https://doi.org/10.1038/s41467-023-37587-6 (Accessed: 14 August 2026).
Leite, M.L. et al. (2021) ‘Artificial intelligence and the future of life sciences’, Drug Discovery Today, 26(11), pp. 2515–2526. doi: 10.1016/j.drudis.2021.07.002. Available at: https://doi.org/10.1016/j.drudis.2021.07.002 (Accessed: 14 August 2026).
Li, Y. et al. (2022) ‘Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor’, Nature Communications, 13, 6891. doi: 10.1038/s41467-022-34692-w. Available at: https://doi.org/10.1038/s41467-022-34692-w (Accessed: 14 August 2026).
Liu, Z. et al. (2021) ‘AI-based language models powering drug discovery and development’, Drug Discovery Today, 26(11), pp. 2593–2607. doi: 10.1016/j.drudis.2021.06.009. Available at: https://doi.org/10.1016/j.drudis.2021.06.009 (Accessed: 14 August 2026).
Medina-Franco, J.L. (2021) ‘Grand challenges of computer-aided drug design: the road ahead’, Frontiers in Drug Discovery, 1, 728551. doi: 10.3389/fddsv.2021.728551. Available at: https://doi.org/10.3389/fddsv.2021.728551 (Accessed: 14 August 2026).
Moingeon, P., Kuenemann, M. and Guedj, M. (2022) ‘Artificial intelligence-enhanced drug design and development: toward a computational precision medicine’, Drug Discovery Today, 27(1), pp. 215–222. doi: 10.1016/j.drudis.2021.09.006. Available at: https://doi.org/10.1016/j.drudis.2021.09.006 (Accessed: 14 August 2026).
Moreno-Benito, M. et al. (2022) ‘Digital twin of a continuous direct compression line for drug product and process design using a hybrid flowsheet modelling approach’, International Journal of Pharmaceutics, 628, 122336. doi: 10.1016/j.ijpharm.2022.122336. Available at: https://doi.org/10.1016/j.ijpharm.2022.122336 (Accessed: 14 August 2026).
Moret, M., Friedrich, L., Grisoni, F., Merk, D. and Schneider, G. (2020) ‘Generative molecular design in low data regimes’, Nature Machine Intelligence, 2, pp. 171–180. doi: 10.1038/s42256-020-0160-y. Available at: https://doi.org/10.1038/s42256-020-0160-y (Accessed: 14 August 2026).
Mullowney, M.W. et al. (2023) ‘Artificial intelligence for natural product drug discovery’, Nature Reviews Drug Discovery, 22, pp. 895–916. doi: 10.1038/s41573-023-00774-7. Available at: https://doi.org/10.1038/s41573-023-00774-7 (Accessed: 14 August 2026).
Murail, S., de Vries, S.J., Rey, J., Moroy, G. and Tufféry, P. (2021) ‘SeamDock: an interactive and collaborative online docking resource to assist small compound molecular docking’, Frontiers in Molecular Biosciences, 8, 716466. doi: 10.3389/fmolb.2021.716466. Available at: https://doi.org/10.3389/fmolb.2021.716466 (Accessed: 14 August 2026).
Nigam, S.K., Bush, K.T., Bhatnagar, V., Poloyac, S.M. and Momper, J.D. (2020) ‘The systems biology of drug metabolizing enzymes and transporters: relevance to quantitative systems pharmacology’, Clinical Pharmacology & Therapeutics, 108(1), pp. 40–53. doi: 10.1002/cpt.1818. Available at: https://doi.org/10.1002/cpt.1818 (Accessed: 14 August 2026).
Pandey, M. et al. (2022) ‘The transformational role of GPU computing and deep learning in drug discovery’, Nature Machine Intelligence, 4, pp. 211–221. doi: 10.1038/s42256-022-00463-x. Available at: https://doi.org/10.1038/s42256-022-00463-x (Accessed: 14 August 2026).
Sadybekov, A.A. et al. (2022) ‘Synthon-based ligand discovery in virtual libraries of over 11 billion compounds’, Nature, 601, pp. 452–459. doi: 10.1038/s41586-021-04220-9. Available at: https://doi.org/10.1038/s41586-021-04220-9 (Accessed: 14 August 2026).
Sadybekov, A.V. and Katritch, V. (2023) ‘Computational approaches streamlining drug discovery’, Nature, 616, pp. 673–685. doi: 10.1038/s41586-023-05905-z. Available at: https://doi.org/10.1038/s41586-023-05905-z (Accessed: 14 August 2026).
Santana, K. et al. (2021) ‘Applications of virtual screening in bioprospecting: facts, shifts, and perspectives to explore the chemo-structural diversity of natural products’, Frontiers in Chemistry, 9, 662688. doi: 10.3389/fchem.2021.662688. Available at: https://doi.org/10.3389/fchem.2021.662688 (Accessed: 14 August 2026).
Schneider, P. et al. (2020) ‘Rethinking drug design in the artificial intelligence era’, Nature Reviews Drug Discovery, 19, pp. 353–364. doi: 10.1038/s41573-019-0050-3. Available at: https://doi.org/10.1038/s41573-019-0050-3 (Accessed: 14 August 2026).
Sové, R.J. et al. (2020) ‘QSP-IO: a quantitative systems pharmacology toolbox for mechanistic multiscale modeling for immuno-oncology applications’, CPT: Pharmacometrics & Systems Pharmacology, 9(9), pp. 484–497. doi: 10.1002/psp4.12546. Available at: https://doi.org/10.1002/psp4.12546 (Accessed: 14 August 2026).
Stein, R.M. et al. (2020) ‘Virtual discovery of melatonin receptor ligands to modulate circadian rhythms’, Nature, 579, pp. 609–614. doi: 10.1038/s41586-020-2027-0. Available at: https://doi.org/10.1038/s41586-020-2027-0 (Accessed: 14 August 2026).
Sukhera, J. (2022) ‘Narrative reviews: flexible, rigorous, and practical’, Journal of Graduate Medical Education, 14(4), pp. 414–417. doi: 10.4300/JGME-D-22-00480.1. Available at: https://doi.org/10.4300/JGME-D-22-00480.1 (Accessed: 14 August 2026).
Sun, D., Gao, W., Hu, H. and Zhou, S. (2022) ‘Why 90% of clinical drug development fails and how to improve it?’, Acta Pharmaceutica Sinica B, 12(7), pp. 3049–3062. doi: 10.1016/j.apsb.2022.02.002. Available at: https://doi.org/10.1016/j.apsb.2022.02.002 (Accessed: 14 August 2026).
Sun, T., He, X., Song, X., Shu, L. and Li, Z. (2022) ‘The digital twin in medicine: a key to the future of healthcare?’, Frontiers in Medicine, 9, 907066. doi: 10.3389/fmed.2022.907066. Available at: https://doi.org/10.3389/fmed.2022.907066 (Accessed: 14 August 2026).
Thornton, J.M., Laskowski, R.A. and Borkakoti, N. (2021) ‘AlphaFold heralds a data-driven revolution in biology and medicine’, Nature Medicine, 27, pp. 1666–1669. doi: 10.1038/s41591-021-01533-0. Available at: https://doi.org/10.1038/s41591-021-01533-0 (Accessed: 14 August 2026).
Tong, X. et al. (2021) ‘Generative models for de novo drug design’, Journal of Medicinal Chemistry, 64(19), pp. 14011–14027. doi: 10.1021/acs.jmedchem.1c00927. Available at: https://doi.org/10.1021/acs.jmedchem.1c00927 (Accessed: 14 August 2026).
Tropsha, A. et al. (2024) ‘Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR’, Nature Reviews Drug Discovery, 23, pp. 141–155. doi: 10.1038/s41573-023-00832-0. Available at: https://doi.org/10.1038/s41573-023-00832-0 (Accessed: 14 August 2026).
Tunyasuvunakool, K. et al. (2021) ‘Highly accurate protein structure prediction for the human proteome’, Nature, 596, pp. 590–596. doi: 10.1038/s41586-021-03828-1. Available at: https://doi.org/10.1038/s41586-021-03828-1 (Accessed: 14 August 2026).
UniProt Consortium (2021) ‘UniProt: the universal protein knowledgebase in 2021’, Nucleic Acids Research, 49(D1), pp. D480–D489. doi: 10.1093/nar/gkaa1100. Available at: https://doi.org/10.1093/nar/gkaa1100 (Accessed: 14 August 2026).
Venkatesh, K.P., Raza, M.M. and Kvedar, J.C. (2022) ‘Health digital twins as tools for precision medicine: considerations for computation, implementation, and regulation’, npj Digital Medicine, 5, 150. doi: 10.1038/s41746-022-00694-7. Available at: https://doi.org/10.1038/s41746-022-00694-7 (Accessed: 14 August 2026).
Vijayan, R.S.K., Kihlberg, J., Cross, J.B. and Poongavanam, V. (2022) ‘Enhancing preclinical drug discovery with artificial intelligence’, Drug Discovery Today, 27(4), pp. 967–984. doi: 10.1016/j.drudis.2021.11.023. Available at: https://doi.org/10.1016/j.drudis.2021.11.023 (Accessed: 14 August 2026).
Vincent, F. et al. (2022) ‘Phenotypic drug discovery: recent successes, lessons learned and new directions’, Nature Reviews Drug Discovery, 21, pp. 899–914. doi: 10.1038/s41573-022-00472-w. Available at: https://doi.org/10.1038/s41573-022-00472-w (Accessed: 14 August 2026).
Yang, T., Li, Z., Chen, Y., Jiang, H. and Zheng, M. (2021) ‘DrugSpaceX: a large screenable and synthetically tractable database extending drug space’, Nucleic Acids Research, 49(D1), pp. D1170–D1178. doi: 10.1093/nar/gkaa920. Available at: https://doi.org/10.1093/nar/gkaa920 (Accessed: 14 August 2026).
Yu, S. et al. (2023) ‘A universal programmable Gaussian boson sampler for drug discovery’, Nature Computational Science, 3, pp. 839–848. doi: 10.1038/s43588-023-00526-y. Available at: https://doi.org/10.1038/s43588-023-00526-y (Accessed: 14 August 2026).
